Method for treating and preventing covid-19

A method of preventing a coronavirus severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection in a patient in need thereof comprising:

• prophylactically administering to the patient in need thereof a therapeutically effective amount of a composition comprising
• at least one nanoparticle having at least one targeting moiety to form a targeted nanoparticle wherein the targeting moiety is a fatty acid selected from the group consisting of linoleic acid (LLA) and linolenic acid (LNA) wherein the targeting moiety is encapsulated in a lipid bilayer of the nanoparticle;
• and
• a therapeutic agent encapsulated within the at least one targeted nanoparticle wherein the therapeutic agent is sitagliptin;
• wherein the targeting moiety binds to the CoV-2 spike protein or ACE2-spike interface of the SARS CoV-2 virus;
• wherein the prophylactic administration of the composition to the patient in need thereof inhibits the coronavirus infection.

A method of inhibiting SARS COVID-19 viral replication comprising:

• contacting a cell with a therapeutically effective amount of a composition, the composition comprising
• at least one nanoparticle having at least one targeting moiety to form a targeted nanoparticle wherein the targeting moiety is a fatty acid selected from the group consisting of linoleic acid (LLA) and linolenic acid (LNA)
• wherein the targeting moiety is encapsulated in a lipid bilayer of the nanoparticle;
• and
• a therapeutic agent encapsulated within the at least one targeted nanoparticle wherein the therapeutic agent is sitagliptin;
• at least one nanoparticle having at least one targeting moiety to form a targeted nanoparticle wherein the targeting moiety is a fatty acid selected from the group consisting of linoleic acid (LLA) and linolenic acid (LNA) wherein the targeting moiety is encapsulated in a lipid bilayer of the nanoparticle;
• and
• a therapeutic agent encapsulated within the at least one targeted nanoparticle wherein the therapeutic agent is sitagliptin;
• wherein the targeting moiety binds to the CoV-2 spike protein or ACE2-spike interface of the SARS CoV-2 virus to inhibit the viral replication.